127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness

T Yoshino,N Hooda,D Younan,K Muro,K Shitara,V Heinemann,B O’Neil,F Rivera Herrero,M Peeters,J Soeda,M Suh,H Reichart,K Mezzi,J Fryzek,V Chia,M Rehn,S Stintzing

doi:10.1016/j.annonc.2023.10.262

127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness

T Yoshino, N Hooda + Show 15 more

https://doi.org/10.1016/j.annonc.2023.10.262

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: Nov 1, 2023

Affiliation: National Cancer Center Hospital East, Aichi Cancer Center, University of Antwerp

#Epidermal Growth Factor Receptor Inhibitors #Bevacizumab In Combination + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

127P A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness

Full Text